Cover Image
市場調查報告書

雙特異性抗體:臨床實驗追蹤調查

Bispecific Antibodies: Clinical Trial Tracker

出版商 ROOTS ANALYSIS 商品編碼 296324
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
雙特異性抗體:臨床實驗追蹤調查 Bispecific Antibodies: Clinical Trial Tracker
出版日期: 2014年02月13日 內容資訊: 英文
簡介

雙特異性抗體(bsAbs)是結合不同的表位為目標的2個單株抗體(以及組織)生成的人工的抗體。產生的抗體有同時繫結2到3個不同表位的親和性。

本報告提供雙特異性抗體(bsAbs)臨床實驗相關情況調查、臨床開發的企業、開發階段、雙特異性系統、及各適應症的明細、各臨床實驗的階段、情形、適應症、贊助商類型、地區、分子及主要國的明細等分析、臨床、前臨床開發的分子的平台詳細內容,SWOT分析等彙整,為您概述為以下內容。

簡介、開發平台詳細內容

  • 章節1:市場概要
  • 章節2:儀表板:開發平台分析
  • 章節3:臨床開發的分子:實驗詳細內容
  • 章節4:前臨床的分子:實驗詳細內容
  • 章節5:實驗對象患者標準/除外標準

市場預測

  • 章節6:市場預測:前提條件
  • 章節7:市場預測:詳細內容
  • 章節8:比較預測方案

產業分析

  • 章節9:產業的SWOT分析

圖表清單

企業清單

目錄
Product Code: CT10002

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.

Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases.

Table of Contents

Introduction and Pipeline Details

  • Section 1: Market Overview
  • Section 2: Dashboard: Pipeline Analysis
  • Section 3: Molecules in Clinical Development: Trial Details
  • Section 4: Molecules in Preclinical Development: Trial Details
  • Section 5: Inclusion / Exclusion Criteria

Market Forecast, 2013 - 2023

  • Section 6: Market Forecast: Assumptions
  • Section 7: Market Forecast: Details
  • Section 8: Comparative Forecast Scenarios

Industry Analysis

  • Section 9: Industry SWOT Analysis

List of Figures

Pipeline Details

  • Figure 1: Bispecific Antibodies in Clinical Development: Distribution by Companies
  • Figure 2: Bispecific Antibodies in Clinical Development: Distribution by Highest Phase of Development
  • Figure 3: Bispecific Antibodies in Clinical Development: Distribution by Type of Bispecific System
  • Figure 4: Bispecific Antibodies in Clinical Development: Distribution by Indication
  • Figure 5: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase and Status (Matrix View)
  • Figure 6: Bispecific Antibodies Clinical Trials: Distribution by Trial Status
  • Figure 7: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase
  • Figure 8: Bispecific Antibodies Clinical Trials: Distribution by Indication
  • Figure 9: Bispecific Antibodies Clinical Trials: Distribution by Sponsor Type
  • Figure 10: Bispecific Antibodies Clinical Trials: Distribution by Region
  • Figure 11: Bispecific Antibodies Clinical Trials: Distribution by Molecules and Countries (Matrix View)
  • Figure 12: Bispecific Antibodies Clinical Trials: Distribution by G7 Countries
  • Figure 13: Bispecific Antibodies Clinical Trials: Distribution by EU5 Countries
  • Figure 14: Bispecific Antibodies in Preclinical Development: Distribution by Indication

Market Forecast

  • Figure 15: Bispecific Antibody Therapeutics Market Forecast, Base Scenario (USD MM)
  • Figure 16: Bispecific Antibody Therapeutics Market Forecast, Scenario Comparison (USD MM)

List of Tables

Pipeline Details

  • Table 1: Molecules in Clinical Development: Pipeline Details
  • Table 2: Molecules in Preclinical Development: Pipeline Details

Market Forecast

  • Table 3: Expected Launch Year of Bispecific Antibodies in Clinical Development

Industry Analysis

  • Table 4: SWOT Analysis

Listed Companies

The following companies and organisations have been mentioned in the report:

  • 1.AbbVie
  • 2.Ablynx
  • 3.Adimab
  • 4.Affimed Therapeutics
  • 5.AGO Study Group
  • 6.Allergan
  • 7.Alligator Bioscience
  • 8.Allozyne
  • 9.Ambrx
  • 10.Amgen
  • 11.Amphivena Therapeutics Inc.
  • 12.Baliopharm
  • 13.Barbara Ann Karmanos Cancer Institute
  • 14.Bayer
  • 15.Beijing ABT Genetic Engineering Technology Co.
  • 16.Biogen Idec
  • 17.Bioline Rx
  • 18.Biotecnol
  • 19.Boehringer Ingelheim
  • 20.Celgene
  • 21.Centre René Gauducheau
  • 22.Chiome Bioscience
  • 23.Chugai
  • 24.Dutalys
  • 25.Eddingpharm
  • 26.Eli Lilly
  • 27.Emergent Biosolutions
  • 28.Fabion Pharmaceuticals
  • 29.Fresenius Biotech
  • 30.F-star
  • 31.Ganymed Pharmaceuticals
  • 32.Garden State Cancer Center at the Center for Molecular Medicine and Immunology
  • 33.Genentech
  • 34.Genmab
  • 35.Gilead
  • 36.Grupo Espa&ntilede;ol de Investigación en Cáncer de Ovario; Neovii Biotech
  • 37.GSK
  • 38.Gustave Roussy, Cancer Campus, Grand Paris
  • 39.Ho Research Consortium
  • 40.ImClone System
  • 41.Immunomedics
  • 42.Innovent Biologics Inc.
  • 43.Institut National de la Santé Et de la Recherche Médicale, France
  • 44.International Joint Cancer Institute, the Second Military Medical University
  • 45.Janssen Biotech
  • 46.Jsehouli
  • 47.Krankenhaus Nordwest
  • 48.Kyowa Hakko Kirin
  • 49.MacroGenics
  • 50.Masonic Cancer Center, University of Minnesota
  • 51.MediaPharma S.R.L
  • 52.MedImmune
  • 53.Memorial Sloan-Kettering Cancer Center
  • 54.Merck
  • 55.Merrimack Pharmaceuticals
  • 56.Merus B.V.
  • 57.Molecular Partners AG
  • 58.Nantes University Hospital
  • 59.National Cancer Institute
  • 60.National Engineering Research Center for Antibody Medicine
  • 61.NeoPharm
  • 62.Neovii Biotech
  • 63.Novartis
  • 64.NovImmune
  • 65.Numab
  • 66.OncoMed Pharmaceuticals
  • 67.Paktis Antibody Services GmbH
  • 68.Pfizer
  • 69.PharmAbcine
  • 70.PLA General Hospital Cancer Center, Beijing
  • 71.Protheragen
  • 72.Radboud University
  • 73.Regeneron Pharmaceuticals
  • 74.Roche
  • 75.Roger Williams Medical Center
  • 76.Sanofi
  • 77.School of Medicine, Shanghai Jiao Tong University
  • 78.Sea Lane Biotechnologies
  • 79.Servier
  • 80.State Key Laboratory of Antibody Medicine and Targeted Therapy
  • 81.Sutro Biopharm
  • 82.Synergys Biotherapeutics Inc.
  • 83.Synimmune GmbH
  • 84.Technische Universität München
  • 85.Trion Pharma
  • 86.University Hospital Tuebingen
  • 87.University Hospital Tuebingen
  • 88.University Witten/Herdecke
  • 89.Xencor
  • 90.Zymeworks
  • 91.Zyngenia
Back to Top